P-glycoprotein expression in HTLV-III cells after treatment with HIV-1 protease inhibitors

Ethnicity and Disease

Volumn 18, Issue 2 SUPPL. 2, 2008, Pages

  Sánchez, María Del C ^a,b   López, Pablo ^a   Vélez, Rosa ^a   Yamamura, Yasuhiro ^a  

^a PONCE SCHOOL OF MEDICINE   (Puerto Rico)

^b AIDS Research Program   (United States)

Author keywords

H9 hTLV IIIce cell line; HIV protease inhibitors; HIV 1; P glycoprotein

Indexed keywords

FLUORESCENT DYE; GLYCOPROTEIN P; MONOCLONAL ANTIBODY; PROTEINASE INHIBITOR; RHODAMINE 123; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ARTICLE; CELL CULTURE; CELL LABELING; CELL LINE; CELL SUSPENSION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; STATISTICAL SIGNIFICANCE; SUPERNATANT; UPREGULATION; VIRUS LOAD; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM;

CELLS, CULTURED; FLOW CYTOMETRY; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; P-GLYCOPROTEIN; RITONAVIR; RNA, VIRAL; SAQUINAVIR; UP-REGULATION; VIRAL LOAD;

EID: 52149095475     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Srinvas R, Middlemas D, Flynn P, Fridland A. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother. 1998;42(12):3157-3162.
2. Ford J, Khoo SH, Back DJ. The intracellular pharmacology of antiretroviral protease inhibitors. J Antimicrob Chemother. 2004;54:982- 990.
3. Sharma RC, Inoue S, Roitelman J, Schimke RT, Simoni RD. Peptide transport by the multidrug resistance pump. J Biol Chem. 1992;267(9).-5731-5734.
4. Kim RB. Drug transporters in HIV therapy. Top HIV Med. 2003; 11 (4): 136-139.
5. Sankatsing SUC, Beijnen JH, Schinkel AH, Lange JMA, Prins JM. P-glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob Agents Chemother. 2004;48(4):1073-1081.
6. Johnstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci. 2000;25:1-6.
7. Eisenbraun MD, Miller RA. MDRlA-encod- ed P-glycoprotein is not required for peripheral T cell proliferation, cytokine release, or cytotoxic effector function in mice. J Immunol. 1999;163:2621-2627.
8. Washington CB, Duran GE, Man MC, Sikic Bl, Blaschke TF. Inreracrion of anri-HlV prorease inhibirors wirh rhe multidrug Transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr. 1998;19(3):203-209.
9. Agrati C, Poccia F, Narciso P, et al. P- glycoprotein expression by peripheral blood mononuclear cells from human immunodeficiency virus-infected patients is independent from response to highly active antiretroviral therapy. Clin Diagn Lab Immunol. 2003; 10(1):191-192.
10. Gutmann H, Fricker G, Drewe J, Toeroek M, Miller DS. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol. 1999:56:383- 389.
11. Meaden ER, Hogard PG, Newton P, et al. P- glycoprotein and MRP-1 expression and teduced ritonavir and saquinavir accumulation in HIV-infected individuals. JAntimicrob Che mother. 2002;50:583-588.
12. Maldonado IM, Almodovar S, Marrero G, et al. HIV-1 infection in dendritic cells in HAART supptessed patients. Retrovirology. 2006;3(Supp 1):39.
13. NIH AIDS Research and Reference Reagent Program Catalog, National Institutes of Health, US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Allergy and Infectious Diseases, 2004-2005; 5-6, 29.
14. Ford J, Meaden ER, Hoggard PG, et al. Effect of protease inhibitor-containing regimens on lymphocyte multidrug resisrance transporrer expression. J Antimicrob Chemother. 2003;52: 354-358.
15. Kim AE, Dinraman JM, Waddell DS, Silverman JA. Saquinavir, an HIV prorease inhibiror, is Transported by P-glycoprorein. J Pharmacol Exp Ther. 1998;286(3):1439-1445.
16. Zhong D, Lu X, Conklin BS, et al. HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells. Arterioscler Thromb Vasc Biol. 2002;22:1560-1566.
17. Ludescher C, Pall G, Irschick EU, Gastl G. Differential activity of P-glycoprotein in normal blood lymphocyte subsets. Br ] Haematol. 1998;101:722-727.
18. Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J. Clin Microbiol. 2003;41(10):4531-4536.
19. Daniel WW. Descriptive statistics. In: Biostatistics: a Foundation for Analysis in the Health Sciences. 7th ed. New York: John Wiley &Sons, Inc, 1999. p. 36-42, 61-62.
20. Huisman MT, Smit JW, Wiltshire HR, Beijnen JH, Schinkel AH. Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the phatmacokinetic properties of saquinavir co-administered with ritonavir. J Pharmacol Exp Ther. 2003;304(2):596-602.